Risk of fatal pulmonary embolism in patients with treated venous thromboembolism

被引:465
|
作者
Douketis, JD
Kearon, C
Bates, S
Duku, EK
Ginsberg, JS
机构
[1] McMaster Univ, Dept Med, Hamilton, ON, Canada
[2] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada
来源
关键词
D O I
10.1001/jama.279.6.458
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context.-The most serious complication of deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE) is fatal PE, However, reliable estimates as to the risk of fatal PE in patients with treated DVT or PE are lacking. Objective.-To provide reliable estimates of the risk of fatal PE and the case-fatality rate of recurrent DVT or PE among patients presenting with symptomatic DVT or PE, during and following 3 months of anticoagulant therapy. Data Sources.-A MEDLINE literature search was performed to identify prospective studies in which patients with symptomatic DVT or PE were treated with 5 to 10 days of heparin and 3 months of oral anticoagulants. We searched the years 1966 to September 1997 using the search terms thrombophlebitis, diagnosis, drug therapy, and prognosis. Current Contents and bibliographies were also scanned. Data Extraction.-Of 137 retrieved studies, 25 studies satisfied predetermined methodologic criteria and were included in the analysis. Data Synthesis.-Among patients presenting with DVT, the rate of fatal PE during anticoagulant therapy was 0.4% (95% confidence interval [CI], 0.2%-0.6%); following anticoagulant therapy it was 0.3 per 100 patient-years (95% CI, 0.1-0.8). The case-fatality rate of recurrent DVT or PE during anticoagulant therapy was 8.8% (95% CI, 5.0%-14.1%); following anticoagulant therapy it was 5.1% (95% CI, 1.4%-12.5%), Among patients presenting with PE, the rate of fatal PE during anticoagulant therapy was 1.5% (95% CI, 0.9%-2.2%); following anticoagulant therapy it was 0 per 265 patient-years (95% CI, 0-3.6), The case-fatality rate of recurrent DVT or PE among patients presenting with PE was 26.4% (95% CI, 16.7%-38.1%). Conclusion.-Among patients with symptomatic PE or DVT who are treated with anticoagulants for 3 months, fatal PE is rare during and following anticoagulant therapy. Patients presenting with PE are more likely to die of recurrent PE or DVT than are patients presenting with DVT.
引用
收藏
页码:458 / 462
页数:5
相关论文
共 50 条
  • [11] Incidence and risk factors of preoperative venous thromboembolism and pulmonary embolism in patients with ovarian cancer
    Liang, Shanhui
    Tang, Wei
    Ye, Shuang
    Xiang, Libing
    Wu, Xiaohua
    Yang, Huijuan
    [J]. THROMBOSIS RESEARCH, 2020, 190 : 129 - 134
  • [12] Risk of recurrent venous thromboembolism and bleeding in patients with acute isolated subsegmental pulmonary embolism
    Girardi, Laura
    Ciuffini, Leonardo Augusto
    Mai, Vicky
    Santagata, Davide
    Ageno, Walter
    Wang, Tzu-Fei
    Carrier, Marc
    Le Gal, Gregoire
    [J]. THROMBOSIS RESEARCH, 2024, 239
  • [13] Simplified pulmonary embolism severity index is associated with recurrent venous thromboembolism in patients with pulmonary embolism
    Zhang Jia-Rui
    Zhou Chen
    Zhou Hai-Xia
    Li Xiao-Qian
    Hu Yue-Hong
    Wang Mao-Yun
    Tang Yong-Jiang
    Yi Qun
    [J]. 中华医学杂志(英文版), 2021, 134 (03) : 359 - 361
  • [14] Simplified pulmonary embolism severity index is associated with recurrent venous thromboembolism in patients with pulmonary embolism
    Zhang, Jia-Rui
    Zhou, Chen
    Zhou, Hai-Xia
    Li, Xiao-Qian
    Hu, Yue-Hong
    Wang, Mao-Yun
    Tang, Yong-Jiang
    Yi, Qun
    [J]. CHINESE MEDICAL JOURNAL, 2021, 134 (03) : 359 - 361
  • [15] Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism
    Vestergaard, P.
    Schwartz, K.
    Pinholt, E. M.
    Rejnmark, L.
    Mosekilde, L.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2010, 21 (09) : 1591 - 1597
  • [16] Incidence and Risk Factors of Recurrent Venous Thromboembolism after Pulmonary Embolism
    Hwang, Hun-Gyu
    Choi, Won-Il
    Lee, Bora
    Lee, Choong Won
    [J]. TUBERCULOSIS AND RESPIRATORY DISEASES, 2019, 82 (04) : 341 - 347
  • [17] Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism
    P. Vestergaard
    K. Schwartz
    E. M. Pinholt
    L. Rejnmark
    L. Mosekilde
    [J]. Osteoporosis International, 2010, 21 : 1591 - 1597
  • [18] Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation Response
    Carrier, Marc
    Le Gal, Gregoire
    [J]. ANNALS OF INTERNAL MEDICINE, 2022, 175 (04) : W13 - W14
  • [19] Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?
    Ainle, Fionnuala Ni
    Kevane, Barry
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2020, (01) : 201 - 212
  • [20] Frequency of venous thromboembolism risk factors in hospitalized patients with pulmonary embolism in routine Russian practice
    Nikulina, N. N.
    Terekhovskaya, Y. U., V
    Iakushin, S. S.
    [J]. EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2021, 20 : 26 - 26